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Abstract
Background: Microarrays strategies, which allow for the characterization of thousands of alternative splice forms in a 
single test, can be applied to identify differential alternative splicing events. In this study, a novel splice array approach 
was developed, including the design of a high-density oligonucleotide array, a labeling procedure, and an algorithm to 
identify splice events.
Results: The array consisted of exon probes and thermodynamically balanced junction probes. Suboptimal probes 
were tagged and considered in the final analysis. An unbiased labeling protocol was developed using random primers. 
The algorithm used to distinguish changes in expression from changes in splicing was calibrated using internal non-
spliced control sequences. The performance of this splice array was validated with artificial constructs for CDC6, VEGF, 
and PCBP4 isoforms. The platform was then applied to the analysis of differential splice forms in lung cancer samples 
compared to matched normal lung tissue. Overexpression of splice isoforms was identified for genes encoding 
CEACAM1, FHL-1, MLPH, and SUSD2. None of these splicing isoforms had been previously associated with lung cancer.
Conclusions: This methodology enables the detection of alternative splicing events in complex biological samples, 
providing a powerful tool to identify novel diagnostic and prognostic biomarkers for cancer and other pathologies.
Background
Alternative splicing of pre-mRNA is a post-transcrip-
tional modification essential for the regulation of gene
expression and function. Through alternative splicing,
multiple transcripts are produced from a single mRNA
precursor, widely expanding proteome diversity. Deep
sequencing applied to diverse human tissues and epithe-
lial cell lines has recently revealed that more than 90% of
human genes undergo alternative splicing [1]. A global
analysis of alternative splicing in the human transcrip-
tome suggested that exon skipping is the most prevalent
form of alternative splicing [2]. Alternative splicing is a
tightly regulated process influenced by cell type, develop-
mental stage, external conditions, etc; however, it is also
associated with multiple disease conditions, including
cancer [3]. For example, cancer-related aberrantly spliced
variants have been shown to be actively involved in the
initiation and/or progression of some types of cancer [4].
Splicing alterations are the consequence of splice-site
mutations, deregulation of splicing regulatory factors, or
both [5]. Tumor-specific variations in splicing may gener-
ate new epitopes that can serve as a starting point for
immune therapy or targeted delivery, as well as for the
development of new diagnostic or prognostic tools [6].
Thus, the identification and molecular characterization
of alternative splicing variants associated with cancer is
currently a very active area of research [7]. In recent
years, powerful techniques for genome-wide identifica-
tion and analysis of alternative splicing isoforms have
been developed. These large-scale high-throughput ana-
lytical methods have been applied to the identification of
differential splicing events in cancer tissues [8]. Exon
microarrays, which contain both known and predicted
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Page 2 of 15exons, have been recently used for this purpose [9-13].
However, since they are not specifically designed to
examine alternative splicing, they fail to detect events
such as the alternative use of 5' or 3' splice sites, intron
retention, or the insertion of cryptic exons. Other splic-
ing-specific microarrays have been developed to cover
most alternative splicing events. These arrays contain oli-
gonucleotide probes that span exon-exon junctions, and
probes positioned within exons to determine individual
exon levels and overall transcript expression. The use of
splice-junction oligonucleotides to analyze splice events
was proposed as early as 1986, when Morgan and Ward
used them to identify differential splice forms of minute
virus in mice cDNA [14]. In 1996, Lockhart et al. reported
one of the first genome-wide microarray studies and sug-
gested the potential of microarrays for the analysis of
alternative splicing [15], but it was not until 2002 that
Clark et al. developed the first microarray containing
splice-junction oligonucleotides to analyze splice events
in yeast [16]. In 2003, Johnson et al. used microarrays
containing oligonucleotide probes complementary to
exon-exon junction sequences to discover new alternative
splice variants in human tissues [17,18]. Also in 2003,
Wang et al. designed an algorithm that aimed to deconvo-
lute the absolute concentrations of each alternative tran-
script present in a complex mixture starting from the
hybridization intensities detected on splice chips [19]. A
new algorithm, called SPACE, has recently been devel-
oped for estimating the number of different splicing iso-
forms (known and unknown), and determining their
structures and relative concentrations [20].
Nonetheless, currently available splice arrays still have
many limitations, mainly due to problems in the design of
the array, the labeling protocol, and data analysis. The
development of robust and efficient splice microarrays
and data-analysis methods will facilitate progress in the
diagnosis, prognosis, and therapy of cancer and other
pathologies. In the present work, we describe a novel
comprehensive methodology for high-throughput profil-
ing of alternative splicing in complex biological samples.
In this methodology, processing of results is based on the
array specific design, which is original and thought spe-
cifically for alternative splicing-discovery. The strategy
consists of optimization of probe design, development of
an unbiased amplification protocol that avoids inappro-
priate transcript coverage due to 3'-biased labeling, and
implementation of detailed data processing. Oligonucle-
otides for the splice array were designed using the Tethys
module (Oryzon Genomics, Barcelona, Spain), an
inhouse oligo design program, complemented with a new
splice-analysis specific module (AltTethys). The algo-
rithm targets the best possible oligonucleotide for each
sequence, rather than imposing a strict oligonucleotide
quality cutoff. A new labeling protocol was developed to
ensure optimal all-length transcript coverage and lineal
amplification, working with small amounts of human
material. To analyze the data, we developed a novel algo-
rithm for the analysis of two-color arrays that allows for a
statistically robust identification of candidate spliced
genes in absence of a prior hypothesis about the contrib-
uting isoforms. We have applied this technology to the
identification of lung cancer-associated splicing variants.
Lung cancer is a devastating disease with few therapeutic
options or suitable molecular biomarkers for early diag-
nosis. The results obtained in this study validated the
utility of the platform, allowing the identification of new
cancer-associated splicing variants with potential utility
in the management of lung cancer.
Results
Development and validation of the unbiased labeling 
protocol
The basis for the reliable detection of splice forms in a
microarray format is a high-quality, non-biased labeling
procedure. Different labeling protocols have been applied
in splicing analyses: (a) Castle et al. developed a PCR +
T7 amplification-based protocol [17]; (b) a commercial
kit is available from Stratagene (Fairplay II) to produce a
labeled first-strand cDNA using random hexamers which
works well if a sufficient amount of starting material is
available; (c) some authors have applied standard 3'-
biased RNA labeling protocols, ignoring the loss of 5'
events.
Considering the valuable and limited starting material
of human clinical samples (total RNA amounts were <
100 ng), as well as ours and others previous experience in
expression microarray studies with cRNA lineal-ampli-
fied material by in vitro transcription [21], we developed
a novel protocol for the detection of alternative splice
events consisting of the following steps (Figure 1a): (a)
extraction of polyA + RNA; (b) first-strand cDNA synthe-
sis employing a chimeric primer including the T7 pro-
moter sequences and a stretch of 6 random bases starting
from 50 ng of polyA + RNA; (c) second-strand cDNA
synthesis; and (d) in vitro transcription using the T7 RNA
polymerase in the presence of a labeled ribonucleotide
(Cy3- or Cy5-CTP). For a first validation of performance,
three different yeast sequences were tested, ranging
between 4500 and 7000 bp to cover any outlier isoform
length. PCR-amplified yeast control sequences and the
corresponding high-quality yeast control oligonucle-
otides were used on the microarray surface to assess
whether a bias with respect to oligonucleotide position
within the transcript had occurred. While some varia-
tions in signal intensity of the different oligonucleotides
were identified, there was no evidence of 3'- or 5'-end bias
(Figure 1b). The same controls were included later in the
lung array design. All human samples (both from normal
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yeast controls to monitor unbiased 3'-5' transcripts cov-
erage and labeling. The yeast control spike-in mix was
prepared in different proportions to check significant sig-
nals throughout the dynamic range of the microarray
experiments. The quantity of the yeast spike-in mix was
optimized to avoid interference with the correct amplifi-
cation of the human samples.
Performance of the array in the evaluation of artificial 
splicing forms
In the next step, the hybridization behavior of high-qual-
ity oligonucleotides for the yeast controls spiked into the
mixture was evaluated and then compared with that of
their corresponding thermodynamical half-oligonucle-
otides. Half-oligonucleotides contain the thermodynamic
half of the total control oligonucleotides (located on
either the 5' or the 3' end) complemented to the size of
the total oligonucleotide with a sequence not expected to
hybridize with the yeast control sequence. The half-oligo-
nucleotides thus represent an event in which the DNA on
one end of the junction is 100% joined to a different DNA
sequence. The use of half-oligonucleotides caused a sharp
decrease in signal intensity compared with the complete
oligonucleotides (Additional file 1: Figure S1), illustrating
that the hybridization temperature and washing condi-
tions were adequate. Nevertheless, most signals did not
drop to zero and there was considerable variation in the
relative signal intensities of both half-oligonucleotides,
indicating that different splice forms can still contribute
to the signal of oligonucleotides containing only half of
the target sequence of a given transcript.
Subsequently, we evaluated the behavior of our splice
array in the detection of aRNA from artificial constructs
of VEGF, PCBP4, and CDC6 genes. Three different iso-
forms were used for VEGF (VEGF121, VEGF165, and
VEGF185), two for PCBP4 (PCBP4 and PCBP4a), and a
single isoform for CDC6. Different isoforms were com-
pared at different concentrations, and their respective
signal intensities on the pilot array were analyzed. A sim-
plified genomic organization of the VEGF and PCBP4
exons, as well as the hybridization scheme, is shown in
Figure 2a, and the different signal intensities for the rele-
vant probes in Figure 2b. The results confirmed the
inherent capacities of the probes to differentiate between
different isoforms. While these results were extremely
promising, it should be noted that they were obtained
with artificial gene fragments present at relatively high
concentrations and in an experimental background of
reduced complexity (and thus with a reduced potential
for cross-hybridization).
Identification of alternatively spliced genes in lung cancer 
and selection of genes for validation
The positive results obtained in the pilot array using
spiked-in isoforms of individual genes encouraged us to
develop a splice array to identify differential splicing vari-
ants in complex biological samples, specifically, in clinical
samples from patients with lung cancer. Based on gene-
expression databases [22,23], 7,958 genes expressed in
normal and tumor lung tissue were selected and used to
design a splice array. The array contained 115,318 exon
probes and 105,141 junction probes for the selected
genes, control probes for the yeast YML059C, YOR328,
and YIL129C transcripts to monitor the labeling proce-
dure, as well as control probes for maize transcripts
(Zm48, Exp and Xet), employed in standard gene expres-
sion analyses by Oryzon (both positive and negative con-
trols at different concentrations).
Differential splicing in the 7,958 genes was then
assessed with the splice array, by hybridization of 20 pairs
of Cy5 labeled tumor and Cy3 labeled normal tissue sam-
ples (TCy5 vs NCy3) prepared from 20 non-small cell lung
cancer (NSCLC) patients (Additional file 2: Table S1), as
Figure 1 Label protocol and control genes. (a) Scheme of the label-
ing protocol, which consisted of the following steps: (I) extraction of 
polyA + RNA, (II) first-strand cDNA synthesis employing a chimeric 
primer including the T7 promoter sequences and a stretch of random 
bases, (III) second-strand cDNA synthesis, (IV) in vitro transcription us-
ing the T7 RNA polymerase in the presence of a labeled ribonucleotide 
(Cy3- or Cy5-CTP). (b) Probe intensities for the yeast control gene frag-
ment YML059C, demonstrating no 3'- or 5'-biased labeling.
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Figure 2 VEGF and PCBP4 isoforms in the pilot experiment. (a) Simplified organization of VEGF and PCBP4, showing the included exon (black) and 
junction (gray) probes, and the hybridization scheme used to evaluate the artificial splicing forms. (b) Detection of VEGF and PCBP4 isoforms in the 
pilot experiment. Probes with differences in signal intensities are indicated by shadowed boxes.
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Page 5 of 15well as three self to self comparisons (NCy5 vs NCy3). The
array data from this study have been submitted to Gene
Expression Omnibus http://www.ncbi.nlm.nih.gov/geo
under accession no. GSE18346. The results were analyzed
with AltPolyphemus (Additional file 2: Supplementary
Methods), which allowed intensity changes of all the oli-
gonucleotides for a given gene to be analyzed with
respect to whether these changes reflected gene expres-
sion changes or isoform changes. Essentially, after pre-
processing (data filtering and normalization) the algo-
rithm first estimates the experimental variability of the
microarray analysis platform using the data of the stan-
dard deviation of the gene probe data on the replicates of
the self to self array.
To identify differences in expression level or splice
forms, "change" is first assessed in the self to self hybrid-
ization. Any change that is not clearly greater than the
inherent variability of the measurement system is consid-
ered "no-change". In the self to self hybridization the
standard deviation (σs,g) can be calculated from the total
gene probe dataset and correlated to the standard devia-
tion of the control probe dataset (σs,g = CF·σc). The data
spreading for the total gene probe set was always a little
higher than that for the control probes (Additional file 2:
Supplementary Methods), which means that the control
probes slightly underestimate the experimental variation.
In tumor vs normal tissue experiments, it is not possible
to measure directly the standard deviation for the no-
change situation for the total gene probe data set (as dif-
ferent samples are compared), but the standard deviation
on the control dataset (σc) can be measured and the stan-
dard deviation for the no-change situation for the total
gene probe dataset for the tumor vs normal array can be
estimated (σ*s,g = CF·σc). Robust change can then be
defined as change below or above the threshold TH = ±
3σ*s,g, although more stringent cut-off can be applied if
desired. Once robust change is defined, the algorithm
examines whether the ratios of the signal in the Cy5 and
Cy3 channels for the exon and junction probes for a given
gene (G) fall within the variability of the experiment
(reflecting genes with regular differential gene expres-
sion) or outside of that variability (potential splice form
variation); i.e. below or above μG ± 3σ*s,g, μG being the
mean value for the ratios of the signal in the Cy5 and Cy3
channels for all the oligos for gene G. Note that μG for a
gene with differential expression will be clearly over the
threshold for the detection of change (the individual
probes are differentially expressed) but the variation
among the different probes will be below that threshold
(Additional file 1: Figure S2c). For a gene to be selected as
a candidate for differential splicing, at least one probe has
to fall outside of the limits of the marked threshold. The
algorithm considers two hypotheses: the observed
hybridization can be explained by a differential mixture
of isoforms or by a whole gene expression change, and
calculates the error of both hypotheses. If there is a possi-
ble isoform change, the algorithm establishes the "Form
Change", an arbitrary and empirically defined figure to
relatively rank the candidates. Figure S3 in Additional file
1 shows a typical output from the AltPolyphemus soft-
ware for a candidate gene susceptible to alternative splic-
ing in lung cancer.
AltPolyphemus can identify splice candidates on data
from individual tumor vs. normal tissue comparisons or
on data from replicate analysis; i.e. on the mean change
for every probe in a given dataset. In performing the pro-
cess on data from a biological replica analysis on a set of
tumor vs. normal tissue comparisons, the aim is not only
to identify individual splice variants but rather to identify
those events that, because of their prevalence, appear to
be more relevant. A strict biological replicate analysis was
performed on the entire lung cancer set in which: (a) all
values for a given oligonucleotide were considered (no
outlier elimination of samples was allowed, as this could
distort our impression of prevalence of events); (b) the
signal cut-off for the oligonucleotide detection was set at
the mean signal + 3σ*s,g of a negative control and the Agi-
lent background control oligonucleotides, thus selecting
for genes expressed clearly above the signal detection
level; (c) the fold change cut-off to make the selection was
set at the mean fold change of the total array data set ±
3σ*s,g, selecting the most relevant changes. Internal
assessment of the performance of the algorithm with
three self-to-self hybridizations was done for experimen-
tal variability. Then AltPolyphemus analyzed the average
value from the biological replicate analysis and generated
a list of genes ranked by the value of their "form change".
This analysis generated 260 potential candidates. Table 1
shows the top 10 genes identified in the analysis.
Validation of splice variants differentially expressed in lung 
cancer
Differences in alternative splicing between primary
NSCLC tissue and normal lung tissue in the ten selected
genes were validated by PCR and sequencing. Validation
was performed with samples from a group of patients
included in the array (Additional file 2: Table S1) and an
independent series of NSCLC patients (Additional file 2:
Table S2). IPO8 was used as the reference gene [24].
Alterations in alternative splicing were confirmed in 4 out
of the 10 genes: CEACAM1, FHL1, MLPH, and SUSD2.
CEACAM1
Ceacam1 (carcinoembryonic antigen-related cell adhe-
sion molecule 1) is a transmembrane protein involved in
intercellular binding and related to several normal and
pathological processes [25]. Alternatively spliced forms
have been identified for CEACAM1 [25]. Our analysis
Pio et al. BMC Genomics 2010, 11:352
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Page 6 of 15predicted changes in the splicing of this gene around
exons 2 and 5. The isoforms generated by alternative
usage of these exons are (Figure 3a): CEACAM1-1 (lack-
ing exons 3-5), CEACAM1-3 (without exon 5), and
CEACAM1-3A (lacking exon 5 and including an addi-
tional exon, hereafter designated as exon Y). To validate
the results obtained in the splice array, PCRs were per-
formed with primers specifically designed to identify
these three different splice forms (Figure 3a and Addi-
tional file 2: Table S3). Samples from primary tumors and
their corresponding normal lung tissue were use to evalu-
ate the expression of these isoforms in samples from 24
NSCLC patients, 11 previously included in the splice
array (Figure 3b) and 13 from an independent series. In
all cases, the identity of the amplified variants was con-
firmed by sequencing. These results clearly showed that
alternative splicing was extensive in lung cancer tissues at
the predicted CEACAM1 region. CEACAM1-1 and
CEACAM1-3 were upregulated in tumors compared
with their corresponding normal samples (p = 0.029 and
p = 0.011, respectively; Additional file 1: Figure S4a).
Thus, 92% (22 of 24) of the tumor samples expressed
CEACAM1-1 whereas only 12 (50%) of the normal lung
samples were positive for this isoform. More interest-
ingly, CEACAM1-1 expression was upregulated in 18
(75%) of the tumors compared with their respective nor-
mal-tissue counterparts. Nineteen tumors (79%) and 12
normal lung samples (50%) expressed CEACAM1-3,
which was upregulated in 17 tumors (71%). The predomi-
nance of the CEACAM1-3A splice variant in cancer tis-
sues was confirmed by conventional PCR (data not
shown) and quantified by real-time PCR in 23 cases (Fig-
ure 3c). CEACAM1-3A was significantly upregulated in
tumors compared with their corresponding normal sam-
ples (p = 0.002). This isoform was upregulated in 19
tumors (83%), with an increase in expression ranging
from 2- to 70-fold (mean ± SD: 14.2 ± 3.3). The alterna-
tive use of exon 7 generates CEACAM1 isoforms with
either a long (L-form) or a short (S-form) cytoplasmic
tail. We analyzed whether the upregulated isoforms
CEACAM1-1, CEACAM1-3, and CEACAM1-3A were L-
or S-forms using primers specifically designed to detect
these variants and concluded that primary lung tumors
predominantly express the S-forms (Figure 3b and Addi-
tional file 1: Figure S4a). Finally, the expression of
CEACAM1-1, CEACAM1-3, and CEACAM1-3A was
determined in a panel of 23 lung cancer cell lines derived
from tumors of all the major histological subtypes (Addi-
tional file 2: Table S4), which demonstrated the expres-
sion of these three isoforms not only in NSCLC but also
in small cell lung cancer (SCLC).
FHL1
The protein Fhl1 (four and a half LIM domains 1) is
mainly involved in skeletal muscle development [26]. Of
the alternative splicing variants described for FHL1 [27-
29], one of the best characterized is FHL1B (also called
SLIMMER), which contains an alternative exon 6, hereaf-
ter designated as exon 6b (Figure 4a). Our splice array
detected differential changes between normal lung and
lung cancer patients in the use of exon 6 and exon 6b.
These changes were validated by PCR in 23 samples, 8
samples from patients included in the splice array and 15
additional samples from the independent set. Conven-
tional PCR followed by sequencing revealed the expres-
sion of two FHL1 isoforms in lung samples: FHL1 and
FHL1B (data not shown). Expression of the two isoforms
was specifically quantified by real-time PCR. In agree-
ment with previous reports in other types of cancer [30-
32], both were found to be downregulated in lung cancer
specimens compared with normal lung tissue (data not
shown). Interestingly, a significant change in the ratio
between FHL1 and FHL1B was also observed (p = 0.003;
Table 1: Genes with potential splice variants differentially expressed between normal lung and lung cancer tissues, as 
determined by the splice array
Ensembl No. Gene Name
ENSG00000123838 C4BPA C4b-binding protein alpha chain
ENSG00000102854 MSLN Mesothelin
ENSG00000164741 DLC1 Rho GTPase-activating protein 7
ENSG00000099994 SUSD2 Sushi domain-containing protein 2
ENSG00000117399 CDC20 Cell division cycle protein 20 homolog
ENSG00000022267 FHL1 Four and a half LIM domains protein 1
ENSG00000115648 MLPH Melanophilin
ENSG00000007402 CACNA2D2 Voltage-dependent calcium channel subunit alpha-2/delta-2
ENSG00000079385 CEACAM1 Carcinoembryonic antigen-related cell adhesion molecule 1
ENSG00000042429 CRSP6 Mediator of RNA polymerase II transcription subunit 17
Pio et al. BMC Genomics 2010, 11:352
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Page 7 of 15Figure 4b). These data validate the differences found by
the splice array and suggest that downregulation of FHL1
in lung tumors differentially affects one of the two
expressed splice forms.
MLPH
Mlph (melanophilin or Slac2-a) is a protein involved in
the transport of melanosomes [33]. The MLPH gene con-
tains 16 exons and encodes a protein of 600 residues.
Results from our splice array suggested changes in splic-
ing around exon 9, and database analysis indicated the
alternative use of this exon in different isoforms (Figure
5a). This alternative isoform generates a protein 28 amino
acids shorter than the normal protein. To validate the
alternative splicing change, 11 samples from patients
included in the splice array were analyzed (Figure 5b). A
specific downregulation of the isoform containing exon 9
was identified in 8 out of the 11 cases studied (73%), con-
firming the results obtained by the splice array (p = 0.036;
Additional file 1: Figure S4b).
SUSD2
Susd2 (sushi domain-containing protein 2) is a recently
identified single-pass type I membrane protein [34]. Only
one SUSD2 mRNA variant has been described to date
(Figure 6a); however, splice array data suggested lung
cancer-associated changes close to the 5' and 3' ends of
the mRNA. To validate these results, normal and tumor-
bearing lung tissues from 21 cases (11 patients used in the
splice array and 10 cases from the independent set) were
analyzed, with reduced expression of SUSD2 detected in
lung cancer tissue compared with normal lung. Regarding
changes in alternative splicing, alterations in the 3' end
but not in the 5' end of the mRNA were found. In particu-
lar, frequent intron retention between exons 11 and 15
was observed (Figure 6b). Inclusion of intronic sequences
within an mRNA is termed exonization. In our study,
Figure 3 CEACAM1-1 splicing isoforms in patients with lung can-
cer. (a) CEACAM1-1 splicing isoforms. The location of the primers used 
in the study is also indicated. (b) PCR amplifications of different 
CEACAM1 splice forms in 11 normal lung tissues and paired tumors 
from patients included in the splice array. CEACAM1-1 was amplified 
with primers 01/08; the L- or S-forms in CEACAM1-1 were evaluated 
with primers 06/09; and CEACAM1-3 was determined with primers 01/
15. IPO8 expression served as the control. Additional PCRs were done 
but are not shown in the figure: CEACAM1-3A was detected with prim-
ers 01/14, and L- and S- forms of CEACAM1-3 and CEACAM1-3A were 
discriminated using primers 20/09 and 18/09, respectively. (c) 
CEACAM1-3A was evaluated by real-time PCR using primers 16-17 in 23 
primary NSCLC tumors and their corresponding normal lung samples. 
** p < 0.01.
a
b
c
***
CEACAM1-4L 
(CEACAM1)
CEACAM1-4S
CEACAM1-3L
CEACAM1-3S
CEACAM1-1L
CEACAM1-1S
CEACAM1-3AL
CEACAM1-3AS
CEACAM1-1
CEACAM1-1L
-1S
CEACAM1-3
IPO8
**
Normal Tumoral
0
5
10
15
20
C
E
A
C
A
M
1-
3A
 / 
IP
O
8
(%
)
C
E
A
C
A
M
1-
3A
 /
 IP
O
8 
(%
)
Figure 4 FHL1 splicing isoforms in patients with lung cancer. (a) 
Exon structure of the 3' end of FHL1 showing alternative use of exon 6b 
in FHL1B. Primers used to quantify the two isoforms expressed by lung 
epithelial cells are also shown. (b) Ratio between the relative expres-
sion of FHL1 and FHL1B in normal lung tissue and primary NSCLC tissue 
as determined by real-time PCR. ** p < 0.01.
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Page 8 of 15exonization of intron 11 was detected in 3 cases (14%),
exonization of intron 12 in 8 cases (38%), exonization of
intron 13 in 5 cases (24%), and exonization of intron 14 in
4 cases (19%). Exonization was not observed in any of the
normal lung samples analyzed. Since in most of the can-
cer samples with exonization only one or two introns
were retained, amplification of contaminating genomic
DNA can be ruled out. Nevertheless, to provide addi-
tional verification, IPO8 and GAPDH were amplified with
primers that allowed the detection of genomic DNA and
cDNA. Bands for GAPDH and IPO8 cDNA but not for
their genomic DNA were obtained (data not shown).
Finally, a panel of 23 lung cancer cell lines was analyzed
for the presence of introns retained in the mature mRNA
(Additional file 2: Table S4). A high frequency of exoniza-
tion events was confirmed within SUSD2 mRNA not only
in NSCLC, but in SCLC as well.
Discussion
This article reports the development of a platform for the
analysis of differential alternative splicing in complex bio-
logical samples and its application to the discovery of
alternative splice forms associated with lung cancer.
Microarray-based methods have been described previ-
ously for the identification of splicing events in different
physiological and pathological conditions [9-13,35-37].
However, in spite of progress in development and inter-
pretation, splice arrays still have many limitations and are
far from attaining the level of standardization and robust-
ness achieved with other high-throughput analytical
methods, such as expression arrays [38]. These limita-
tions involve several steps of the process, such as the
array's design, the labeling protocol, and data analysis.
The detection of alternative splicing using arrays con-
taining only exon probes is based on the idea that a dis-
crete set of exons, some of which are skipped in the event
of alternative splicing, constitute the final mRNA. But
this view is largely simplified, as exons may be longer or
shorter, junctions may form at different positions, and
intron sequences between two exons may be retained. In
addition, some exons are very small, to the extent that any
oligonucleotide designed to detect them would require
the inclusion of sequences from flanking exons. Even in
the case of splice arrays that contain junction probes, the
design of these probes is challenging. Most splice arrays
make use of oligonucleotides of constant length or Tm,
but they do not consider that the contributions of the two
sequences on either side of the junction may be substan-
tially different due to differences in sequence composi-
tion. Probe quality is also affected by the strong spatial
restrictions on oligonucleotide design required for the
analysis of differential splicing. This leads to an inevitable
breakdown of the strict thermodynamic and specificity
criteria that are usually imposed on the design of an
expression microarray. As for the labeling protocols,
methods for standard gene-expression analysis are gener-
ally based on labeling from the 3' end, followed by detec-
tion with 3'-end probes. However, in a splicing analysis,
the sequences of the oligonucleotides present in the array
need to spread over the complete length of the tran-
scripts, and the quality of the analysis strongly depends
on homogeneous labeling of the RNA. If the labeling pro-
tocol is inappropriate, hybridization of insufficient mate-
rial create "absent" values; more importantly, if the
intensity of a fraction (but not all) of the probes for a
given gene drops below the detection limit, normal gene
expression changes will lead to incorrect detections of
splice changes. Consequently, the rate of false-positive
discovery would be considerable for genes expressed at
low levels. Additionally, in a splice array, data processing
and the identification of genuine differential splicing
events are more complex than in standard gene-expres-
Figure 5 MLPH splicing isoforms in patients with lung cancer. (a) 
Exon structure of MLPH and the splice variant in which exon 9 is 
skipped. Primers used for amplification of both isoforms are also indi-
cated. (b) PCR amplification of both isoforms in samples from 11 
NSCLC patients included in the splice array.
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Figure 6 SUSD2 splicing isoforms in patients with lung cancer. (a) 
Exon structure of SUSD2. The position of the primers used to study the 
exonization of introns 11, 12, 13 and 14 is shown. (b) Determination of 
the presence of intron retention in samples from 11 NSCLC patients in-
cluded in the splice array. The lower bands in each gel represent cDNA 
without exonization; the upper bands correspond to the retention of 
introns (the presence of an amplified band is indicated by "+"). IPO8 ex-
pression served as the control.
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Page 9 of 15sion arrays and require specific analytical algorithms.
This is due to the larger variation in thermodynamic con-
ditions and possible cross-hybridization or folding of
sub-optimally designed probes. Finally, an additional
requirement for the analytical algorithm is the need to
distinguish differential splicing from changes in gene
expression levels. The methodology described in the
present work has addressed all these limitations.
In designing the probes, we applied an oligonucleotide
design algorithm that performs an in silico thermody-
namic simulation of the hybridization procedure. The
algorithm targets the best possible oligonucleotide for
each sequence, rather than imposing a strict oligonucle-
otide quality cutoff. Several control oligonucleotides were
also designed and included in the array to control labeling
and hybridization processes. The proper design and
inclusion of control oligonucleotides, as well as appropri-
ate use of the data generated by these controls in data
processing, are especially relevant considering that tech-
nical variability can be introduced by the addition of steps
in the labeling protocol necessary to avoid labeling biases.
To analyze the data, we developed new software to inter-
pret the intensity changes of all the oligonucleotides for a
given gene and to decide whether they reflected expres-
sion changes or isoform changes.
The efficacy of our new methodology and its potential
usefulness in a clinical setting were tested in an applica-
tion designed to identify genes differentially spliced in
primary lung tumors. Lung cancer is the leading cause of
cancer deaths worldwide [39], with the major form,
NSCLC, accounting for about 80% of all lung cancers. In
spite of advances in early detection and treatment, overall
5-year survival rates for NSCLC remain at about 15%
[40], underlining the need for a better understanding of
the molecular pathogenesis of NSCLC. It has been pro-
posed that modifications in the concentration, localiza-
tion, composition, or activity of RNA-binding proteins
acting as splicing regulatory factors induce the splicing
alterations characteristic of lung cancer [41]. In this
sense, the abnormal expression of heterogeneous nuclear
ribonucleoproteins (hnRNP) in NSCLC clinical samples
and animal models suggests that tumors develop specific
hnRNP profiles [42-44]. This alteration would generate
clinically relevant alternative splice forms contributing to
lung carcinogenesis. A recent report presented a
genome-wide analysis of alternative splicing events in
lung adenocarcinoma [13]. In that study, the authors
obtained a list of cancer-related candidate genes showing
alternative splicing events and implicated in cancer.
In the present study, the presence of differentially
expressed splice variants in NSCLC was evaluated using a
splice array designed to detect near 8000 genes known to
be expressed in lung tissue. Analysis of the splice array
data generated a list of candidates, from which 10 genes
were selected for validation. Since one of the main pur-
poses for this selection was to validate the quality of the
detection process, no biological criteria were considered
in the selection of the candidate genes at this point. RT-
PCR experiments, followed by sequencing, were used to
validate the results from the array, with changes in alter-
native splicing confirmed in four genes. As expected, the
validation success was below the rates obtained in gene
expression studies and was comparable to the rates
reported in previous splicing studies [13,18]. Regardless
of the platform and algorithm used to detect differential
splicing, by microarray or other hybridization-based
analysis, it is important to realize that the technology is
inherently sensitive to a number of errors that can lead to
the incorrect identification of alternative splicing. For
example, low-level expression can lead to the erroneous
identification of splice events, due to the fact that not all
oligonucleotides generate the same level of signal, and the
signal of low-responsive oligonucleotides can drop below
the detection limit thereby generating false "form
changes" when the overall expression level differs
between Cy3 and Cy5 channels. Cross-hybridization,
obviously, is another potential cause of the detection of
false "form changes". While cross-hybridization can
sometimes be suspected when the higher signal of one
oligonucleotide compared to the others cannot be justi-
fied by a much higher Tm or a sub-optimal design, it will
generally go unnoticed until further detailed analysis is
performed. Moreover, there is no guarantee that all possi-
ble gene-structure changes are analyzed in the validation
process, unless a very extensive validation approach is
applied for any gene of interest (which may be hampered
by the availability of clinical material). The four genes
with lung cancer-associated alternative splice forms
newly identified in this study were: CEACAM1, FHL1,
MLPH, and SUSD2.
Ceacam1 is a CEA-related cell adhesion molecule
downregulated in several human cancer types, including
prostate, breast, and colorectal cancers [25]. CEACAM1
has been described as a lung tumor marker, and its
expression has been associated with the prognosis of lung
adenocarcinoma [45-47]. Two major CEACAM1 iso-
forms have been described: a long (L-) form and a short
(S-) form, which, respectively, include or exclude exon 7.
The exclusion of exon 7 generates a proximal stop codon
that translates into a shorter cytoplasmic domain. Tumor
cells transfected with CEACAM1-1L are less tumori-
genic, suggesting that the L-form functions as a tumor
suppressor gene [48]. Wang et al. reported that
CEACAM1-4S is the predominant isoform in NSCLC tis-
sues, whereas in normal lung tissues the main isoform is
CEACAM1-4L [49]. This splice pattern was recently con-
firmed [13]. In addition to confirming previous data, our
analysis predicted other changes in the splicing of
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Page 10 of 15CEACAM1 around exons 2 and 5, which were validated
by PCR. For the first time, it was demonstrated that lung
tumors frequently overexpress three splice isoforms:
CEACAM1-1, CEACAM1-3, and CEACAM1-3A. The
alternative use of these exons affects different Ig-like
structural domains in the extracellular portion of the
respective proteins.
The family of four and a half LIM (FHL) proteins, also
known as skeletal muscle LIM proteins (SLIM), is charac-
terized by four complete LIM domains preceded by an N-
terminal half LIM domain [50]. LIM domains are
cysteine-rich, double zinc-finger motifs involved in pro-
tein-protein interactions. FHL has been shown to regu-
late tissue differentiation, proliferation, adhesion,
migration, cytoskeletal organization [51,52], and recently,
to play a role in carcinogenesis through a TGF-β-like sig-
naling pathway [53]. Four and a half LIM domains 1 (Fhl1
or Slim1) is a member of this family and has likewise been
implicated in skeletal muscle development [26] as well as
in the pulmonary vascular remodeling underlying pulmo-
nary hypertension [54]. Interestingly, Fhl1 is downregu-
lated in many types of solid malignancies and it exhibits
tumor suppressor activity [30-32]. Among the splice vari-
ants described for FHL1, in our study the expression of
two of them, FHL1 and FHL1B, was identified in lung
samples. In agreement with previous reports, clear down-
regulation in the expression of the FHL1 gene was
detected in lung cancer specimens. More importantly, we
determined that the downregulation of FHL1 is signifi-
cantly higher than that of FHL1B. The two proteins are
identical over the first three LIM domains but FHL1B
contains a distinct C-terminus (96 amino acids) with
three potential bipartite nuclear localization signals, a
putative nuclear export sequence, and a binding motif for
the transcription factor RBP-J [27,28]. Whereas FHL1 is
mainly located at focal adhesions, FHL1B is predomi-
nantly a nuclear protein and has unique physiological
functions, including the regulation of Notch signaling
through its association with RBP-J [55]. Notch signaling
profoundly influences the regulation of tumor progres-
sion, specifically, tumor cell proliferation, differentiation,
apoptosis, and angiogenesis [56].
Mlph is a member of the synaptotagmin-like protein
family and is involved in the transport of melanosomes
[33]. These lysosome-related organelles are specialized in
the synthesis and distribution of melanin. Mlph is an
essential member of the melanosome trafficking com-
plex, acting as a link between Rab27a and myosin Va
[57,58]. It may also be involved in the trafficking of epi-
thelial Na + channel in cells of the collecting duct of the
kidney [59]. Mlph contains an N-terminal Slp homology
domain (SHD) involved in binding to Rab27a, a myosin-
binding domain (MBD) in its middle region, and a C-ter-
minal actin-binding domain (ABD). Here, we demon-
strated that lung tissue expresses at least two isoforms of
MLPH, one with and one without exon 9. Skipping of this
exon generates a protein 28 amino acids shorter than the
normal protein, without affecting any of the three charac-
terized functional domains. In lung tumors, there is spe-
cific downregulation of the isoform containing exon 9.
The recently identified Susd2 is a single-pass type I
membrane protein with an extracellular portion that con-
tains somatomedin B, AMOP, von Willebrand factor type
D, and sushi/CCP/SCR domains [34]. Although its physi-
ological function is still unknown, overexpression of
Susd2 is thought to suppress tumorigenicity [34,60]. In
agreement with this postulated role for the protein, we
observed reduced expression of SUSD2 in lung cancer tis-
sues. Interestingly, intron retention was frequently
detected between the last exons of the mRNA. Inclusion
of intronic sequences within an mRNA is termed
exonization. Although this modification is the rarest type
of alternative splicing found in normal cells, exonization
events in cancer cells are frequent and may be associated
with impairments in splicing regulatory factors [61]. The
exonization of introns affects the extracellular portion of
SUSD2 in that the translation of intron 11 introduces a
premature stop codon which disrupts the von Willebrand
factor type D domain at amino acid 631. Exonization of
intron 12 generates a protein whose last 41 amino acids
are substituted by 68 new amino acids (38 coded by
intron 12 and 30 new amino acids translated as conse-
quence of a frame-shift in the reading frame of exon 13).
Translation of intron 13 generates a protein with a new
sequence of 23 amino acids from position 781 (without
affecting any known functional domain), while retention
of intron 14 introduces a premature stop codon, eliminat-
ing seven amino acids at the C-terminal end.
Conclusions
We have developed and tested a novel platform for high-
throughput analysis of alternative splicing events in bio-
logical samples. The application of this methodology will
aid in understanding the functional relevance of splice
variants in pathological conditions and facilitate the iden-
tification of new biomarkers and targets for therapy. To
prove the usefulness of this platform, this methodology
was used to identify cancer-associated splice variants in
lung cancer. Differentially expressed splice variants of
four genes were identified, with potential utility in the
diagnosis of lung cancer. Additional work is in progress to
analyze the relevance of these newly characterized can-
cer-associated isoforms as well as to validate additional
candidates from data obtained in the splice array.
Methods
Clinical samples
Primary tumors and their corresponding normal lung tis-
sues were obtained from patients with non-small cell lung
cancer (NSCLC) treated with curative resectional surgery
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or at the Hospital Marqués de Valdecilla (Santander,
Spain). None of the patients received chemo- or radio-
therapy prior to surgery. The study was approved by the
ethics committees of the participating institutions and
informed consent was obtained from each patient. Surgi-
cally removed samples were immediately frozen in liquid
nitrogen and stored at -80°C until use. A portion of each
sample was sectioned in a cryostat and mounted onto
slides. After fixation, these samples were stained with
hematoxylin and eosin, and then carefully examined by
two experienced researchers. Samples containing less
than 70% tumor cells were discarded. The 42 specimens
selected for the study were divided into two groups: one
for discovery (n = 20; Additional file 2: Table S1) and one
for validation (n = 22; Additional file 2: Table S2).
Lung cancer cell lines
All lung cancer cell lines were obtained from the Ameri-
can Type Culture Collection (ATCC), except HCC44,
HCC827, EPLC-272H, and HCC15, which were obtained
from the German Collection of Microorganisms and Cell
Cultures (DSMZ). Cells were grown in RPMI supple-
mented with 2 mM glutamine, 10% fetal bovine serum
(FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin.
New splice array design
Oligonucleotides for the splice array were designed using
Tethys software (Oryzon Genomics, Barcelona, Spain)
complemented with a new splice-analysis specific module
(AltTethys) generated for the present study. Tethys is an
oligonucleotide design algorithm that performs in silico
thermodynamic simulation of the hybridization proce-
dure previously used in the design of gene expression or
genome hybridization arrays. The array design included
exon and junction oligonucleotides to detect genes
expressed in the human samples, and oligonucleotides for
the detection of artificial spiked-in control genes from
yeast. The control oligonucleotides served a dual pur-
pose: to control labeling and hybridization, and to pro-
vide relevant statistical information for data analysis.
The overall flow of the algorithm used for gene-probe
design in the present work is diagrammed in Figure 7.
Transcript (exon and junction) information was extracted
from Ensembl database (NCBI 36, release 40). A target-
sequence database was generated, including all the possi-
ble transcripts for a given gene specified in the database.
The new AltTethys module located the exons corre-
sponding to each gene and selected the target sequences,
which had a target length of 36 bp. If an exon was less
than 36 bp long, additional bases were included from the
neighboring exons on both sides (Additional file 1: Figure
S5). For each transcript, junction target sequences were
selected for each known exon-exon junction, including 25
bp at each boundary side and, if an exon was smaller than
25 bp, sequences were added from neighboring exons
(Additional file 1: Figure S5). Tethys was then used to
design oligonucleotides for the target sequences. Due to
the very small degree of freedom resulting from restric-
tions on oligonucleotide locations, the design targeted
the best possible oligonucleotide for each sequence rather
than imposing a strict oligonucleotide quality cutoff.
However, oligonucleotide quality was considered in the
interpretation of the results (see below). Probe synthesis
was outsourced to Agilent Technologies.
Exon probes
For exon probes, the target Tm was 75°C and the Tm
range 70-80°C, with a length modulation of 30-36 bp and
a temperature limit of 60°C for cross-hybridization. If no
specific exon probe complied with these conditions, the
best possible oligonucleotide (minimal cross-hybridiza-
tion Tm and secondary structure folding Tm) was
selected.
Junction probes
Junction probes were designed using junction target
sequences with a total maximum length of 50 bp. Probe
sequences with different lengths but with Tm values as
Figure 7 Flow diagram of splice array oligonucleotide design. The 
oligonucleotides were designed using Tethys software (Oryzon Ge-
nomics) complemented with a novel splice-analysis module (AltT-
ethys) specifically developed for the present study.
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Page 12 of 15similar as possible for the two sections of the oligonucle-
otide flanking both sides of the junction were selected.
The total length of the junction probes ranged from 25 to
42 bp. Among all possible sequences, the oligonucleotide
with a Tm as close as possible to the target temperature of
75°C was selected. Finally, the oligonucleotide was
checked for Secondary Structure Folding Tm and Maxi-
mum Cross-Hybridization Tm using the Tethys oligonu-
cleotide design backend, taking note of the potential for
cross-hybridization.
Control probes
An extensive battery of probes was included to control
labeling and hybridization processes and to provide rele-
vant statistical information for data analysis: (a) three
yeast artificial target sequences were spiked into the
hybridization mixture at three different concentration
levels but balanced in the Cy3 and Cy5 channels; (b) opti-
mum oligonucleotides (in terms of specificity and ther-
modynamics) distributed over the length of the target
sequences to assess labeling bias; (c) half oligonucleotides
(generated by splitting optimum oligonucleotides into
two thermodynamically equivalent halves comple-
mented with stretches of AT at the 5' or 3' end) to simu-
late differential splicing at the splice-donor or splice-
acceptor site. These probes were included more than ten
times in the array in order to determine intra-array vari-
ability.
In addition, a higher number of positive and negative
control probes were distributed over the array surface
(maize expansin, ZmMYB42, and xyloglucan endo-trans-
glycosylase). These probes were used to assess detection
limits and range, to verify spatial homogeneity, and to
determine experimental within-array variation.
Cloning of artificial constructs for VEGF, PCBP4, and CDC6
The performance of the splice array was tested using a
pilot array designed to identify different transcripts of
three genes: VEGF, PCBP4, and CDC6. Artificial tran-
scripts were generated for three VEGF isoforms
(VEGF121, VEGF165, and VEGF185) [62], two PCBP4 iso-
forms (PCBP4 and PCBP4a) [44], and the only known
CDC6 isoform.
Preparation of yeast controls
Three yeast sequences of DNA were amplified by PCR
from genomic DNA of Saccharomyces cerevisae strain
S288C using two chimeric primers, where a primer con-
sisted of a T7 promoter and the gene specific sequence,
and the other primer consisted of a tail of 20 timidines
and the gene specific sequence. These three genes were:
YIL129C (7100 bp), YML059C (4900 bp) and YOR328W
(4600 bp). They were amplified by PCR with 32 ng of
genomic DNA from yeast and using a combination of two
polymerase TaqI:Pfu (20:1). cRNA was generated using
an in vitro transcription system (T7 Megascript kit;
Ambion) getting the final artificial unique splice forms.
The sequences were spiked into the samples prior to
labeling.
RNA extraction and labeling
Total RNA from paired normal and tumor samples from
lung tissues was extracted using the RNeasy Extraction
Kit (Qiagen) according to the manufacturer's instruc-
tions, with minor modifications. RNA quality was
assessed using an Agilent Bioanalyzer 2100 and quanti-
fied using a Nanodrop ND-1000 spectrophotometer.
Samples with an RNA integrity number (RIN) below 7
were excluded from further analysis. PolyA + RNA was
extracted using Dynabead magnetic particles. To obtain
homogeneous labeling of the RNA across the entire
length of the transcript, a novel labeling procedure,
described in the Results section, was developed. Fifty
nanograms of PolyA + RNA from normal tissue was
labeled with Cy3 and the same amount of PolyA + RNA
from tumor samples with Cy5. In addition, 50 ng of PolyA
+ RNA from normal tissue was labeled with Cy5. Prior to
labeling, artificial yeast transcipts were spiked into all
polyA + samples mixtures. The quality of the labeled
samples was verified using the Agilent 2100 Bioanalyzer
and sample concentration was determined using the
Nanodrop ND-1000 spectrophotometer.
Array hybridization and data acquisition
Labeled normal tissue cRNA (4.5 μg) was mixed with the
same amount of labeled tumor cRNA from the same
patient, and equal quantities of Cy3 and Cy5 labeled Xet
and Zm42 cRNA controls were spiked in to serve as
hybridization controls. The cRNA was mixed with 25 ×
fragmentation buffer (Agilent) and incubated at 60°C for
30 min to fragment RNA. Afterwards, 250 μl of 2 ×
hybridization buffer (Agilent) was added to stop the frag-
mentation reaction and the mixture was hybridized on
the array. Slides were incubated for 17 h at 60°C in an
Agilent DNA Hybridization Oven (G2545A) with the
rotation setting at 4 rpm. A total of twenty Cy3 labeled
normal and Cy5 labeled tumor lung cancer samples, were
cohybridized pairwise on the splice array as well as three
Cy3 labeled normal and Cy5 labeled normal samples. Raw
data were acquired using an Agilent DNA Microarray
Scanner and Agilent Feature Extraction Software (V.9.1).
The general reproducibility of the hybridization platform
(labeling procedure, hybridization, and detection) was
assessed by means of self to self hybridization; the stan-
dard deviation of the fold change of all oligonucleotides
was 0.093.
Data processing
For data processing, a novel algorithm that distinguished
between changes in gene expression and splicing varia-
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forms is more complex than the analysis of differential
gene expression, due to a higher variation in thermody-
namic conditions and possible cross-hybridization and
folding of sub-optimally designed oligonucleotides. In
addition, compared with regular gene expression analy-
ses, additional variation can be introduced due to the
incorporation of extra steps in the labeling protocol. This
gives a special importance to the incorporation of spiked-
in controls in the array design and their use in data pro-
cessing. The data processing procedure (which is detailed
in Additional file 2: Supplementary Methods) was divided
into four steps: data filtering and normalization, probe
spot calibration, gene probe statistical analysis, and iso-
form analysis. Data processing is discussed more exten-
sively in Additional file 2: Supplementary Methods.
Validation of cancer-associated splice variants by PCR
Results obtained in the splice array were validated by
PCR. Two micrograms of RNA from the clinical samples
were reverse transcribed. Genomic DNA contamination
was controlled in each RNA sample using a reaction mix
lacking reverse transcriptase. One microliter of cDNA
diluted 1:10 was used for PCR amplification, and the PCR
products were electrophoresed in agarose gels. For
sequencing, the amplified bands were purified using the
Qiagen MinElute PCR Purification Kit and sequenced in
an ABI377 sequencer (Perkin-Elmer Applied Biosystems).
Real-time PCR was performed using SYBR Green PCR
Master Mix (Applied Biosystems) in the Applied Biosys-
tems 7300 Real-Time PCR System. The reactions were
carried out according to the manufacturer's instructions.
Each sample was analyzed in triplicate. Relative levels of
expression were determined by the Ct method using
IPO8 as the reference [24]. Primers used for validation
are shown in Additional file 2: Table S3.
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